EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

LakeShore Biopharma Co., Ltd (LSBCF) fair value: what the stock is really worth

As of Jun 29, 2026: fair value of LakeShore Biopharma Co., Ltd $0.07, price $0.07, upside -2.7%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN KYG9845F2080

LB LakeShore Biopharma Co., Ltd logo Thin data Sep 24, 2026

LakeShore Biopharma Co., Ltd

LSBCF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0652 · Fairly valued (−2.7%)
!Quality 36/100
!Expensive Growth (revenue 3y +6.9 %/yr)
!Loss-making · -16.3% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (4/8)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch LakeShore Biopharma Co., Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$101.40 $0.0278 Fair Value $0.0652 Aug 2021 Jun 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

59‑month range $0.0278 – $101.40 · fair‑value band $0.0540 – $0.0863 · the $0.0670 price screens above the $0.0652 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow LakeShore Biopharma Co. in your weekly email

Every Wednesday you see whether LakeShore Biopharma Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.

Show more

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.

Stock analysis

LakeShore Biopharma Co., Ltd (LSBCF) currently trades at $0.0670, while our model-based Fair Value estimate is $0.0652, so the stock looks roughly fairly valued today (gap 2.8%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0540 (bear) to $0.0863 (bull), the price of $0.0670 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LakeShore Biopharma Co., Ltd reported revenue of 615M CNY in FY2025 versus 257M CNY in FY2021, a compound +24.4%/yr. Reported net income was −100.0M CNY in FY2025.

Key figures

Market cap $2.8M · EPS (TTM) $−0.7700 · Net margin −16.3% · Return on equity −18.4% · Return on assets (EBIT) −27,566% · Operating margin −68.8% · Revenue (TTM) 615M CNY · Revenue growth (YoY) +27.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and 141% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −3%, LSBCF screens richer than that median.

Fair Value models

Bear $0.0540 Fair Value $0.0652 Bull $0.0863
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.9100 $1.21 $1.81 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.9100 $1.21 $1.81 54

Open the full fair value analysis →

Notify me when LSBCF reaches fair value

Put LSBCF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 37 · Market factors (momentum, volatility) 24

Profitability 19
Margins and returns on capital today
Quality Growth 81
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 28
Balance sheet, leverage, solvency risk
Investment 65
Disciplined investing over empire-building
Low Volatility 31
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−49.0% (2021) → −14.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LSBCF, get fair value alerts →

Compare LakeShore Biopharma Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −2.7% · Above median
Profitability
Return on assets −2.2% · Above median
Net margin (TTM) −16.3% · Below median
Operating margin (TTM) −68.8% · Bottom 25%
Growth and dividend
Revenue growth 27.7% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)30 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LakeShore Biopharma Co., Ltd · Fair Value
$0.0652 −3%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LakeShore Biopharma Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/LSBCF

Frequently asked questions

Is LakeShore Biopharma Co., Ltd (LSBCF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0652 versus the last price from Jun 29, 2026 of $0.0670, about −3% upside (fairly valued).
What is the fair value of LSBCF?
Our model-based fair value for LakeShore Biopharma Co., Ltd is $0.0652 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jun 29, 2026): $0.0670.
What is the quality score of LSBCF?
LakeShore Biopharma Co., Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LakeShore Biopharma Co., Ltd (LSBCF)?
Our model-based price target is the fair value of $0.0652 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.0540, optimistic scenario $0.0863. It is a calculation from audited fundamentals, not an analyst target.
What is the LakeShore Biopharma Co., Ltd stock forecast for 2026?
Our models put fair value at $0.0652, about −3% upside versus the last price from Jun 29, 2026 of $0.0670 (fairly valued). Cautious scenario $0.0540, optimistic scenario $0.0863. The calculation is refreshed regularly with new filings.
What is the revenue of LakeShore Biopharma Co., Ltd (LSBCF)?
LakeShore Biopharma Co., Ltd reported trailing-twelve-month revenue of about 615M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of LakeShore Biopharma Co., Ltd (LSBCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LakeShore Biopharma Co., Ltd it is $0.0652 per share (as of Sep 24, 2026), against a price of $0.0670. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is LakeShore Biopharma Co., Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LSBCF trades above its calculated fair value: price $0.0670, fair value $0.0652, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LSBCF?
No. The price is what the market pays today ($0.0670); the fair value is what the company's own numbers justify ($0.0652). For LakeShore Biopharma Co., Ltd the two are $0.0018 per share apart. That gap is exactly why we show both numbers side by side.
How much is LakeShore Biopharma Co., Ltd worth?
The market values LakeShore Biopharma Co., Ltd at about $2.8M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0670; our models calculate a fair value of $0.0652 per share.
What do the bullish and bearish scenarios say about LSBCF?
Our models span a range for LakeShore Biopharma Co., Ltd: cautious scenario $0.0540, base $0.0652, optimistic $0.0863 per share (as of Sep 24, 2026, price $0.0670). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LakeShore Biopharma Co., Ltd (LSBCF)?
Balance-sheet figures for LakeShore Biopharma Co., Ltd (as of Sep 24, 2026): return on equity −18.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is LSBCF from its 52-week high?
LakeShore Biopharma Co., Ltd trades at $0.0670, about 95% below its 52-week high of $1.38 and 141% above the low of $0.0278 (as of Jun 29, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0652 is for.
Which stocks are comparable to LakeShore Biopharma Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LakeShore Biopharma Co., Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0670, calculated fair value $0.0652 (−3%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LSBCF calculated?
We run LakeShore Biopharma Co., Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0652, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. LakeShore Biopharma Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LakeShore Biopharma Co., Ltd (LSBCF)?
The latest price we hold is from Jun 29, 2026 and stands at $0.0670. Our model-based fair value is $0.0652, about −3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LakeShore Biopharma Co., Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of LakeShore Biopharma Co., Ltd

How large is the market capitalisation of LakeShore Biopharma Co., Ltd (LSBCF)?
The market capitalisation of LakeShore Biopharma Co., Ltd is $2.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of LakeShore Biopharma Co., Ltd (LSBCF)?
Earnings per share at LakeShore Biopharma Co., Ltd are $−0.7700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LakeShore Biopharma Co., Ltd (LSBCF)?
The net margin of LakeShore Biopharma Co., Ltd is −16.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LakeShore Biopharma Co., Ltd (LSBCF)?
The return on equity (ROE) of LakeShore Biopharma Co., Ltd is −18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LakeShore Biopharma Co., Ltd (LSBCF)?
On an EBIT basis the return on assets of LakeShore Biopharma Co., Ltd is −27,566% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LakeShore Biopharma Co., Ltd (LSBCF)?
The operating margin of LakeShore Biopharma Co., Ltd is −68.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LakeShore Biopharma Co., Ltd (LSBCF)?
Revenue at LakeShore Biopharma Co., Ltd is growing +27.7% versus a year earlier (3y avg +6.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LakeShore Biopharma Co., Ltd (LSBCF) generate?
The free cash flow of LakeShore Biopharma Co., Ltd is −139M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LakeShore Biopharma Co., Ltd (LSBCF) carry?
The net debt of LakeShore Biopharma Co., Ltd is 386M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch LakeShore Biopharma Co., Ltd in the live analysis

One click puts LakeShore Biopharma Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.